Insider Trade: Jennifer Li Obtained 40,000 Shares of Philip Morris International Inc. (PM); Arrowhead Pharmaceuticals, Inc. (ARWR) Had 6 Bulls

May 16, 2018 - By John Hoffman

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Logo

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Coverage

Among 8 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Arrowhead Research Corp had 28 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has “Hold” rating given on Tuesday, March 27 by FBR Capital. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) earned “Neutral” rating by Piper Jaffray on Wednesday, November 30. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) earned “Buy” rating by Piper Jaffray on Monday, November 27. The rating was maintained by Piper Jaffray on Thursday, September 14 with “Hold”. The firm has “Hold” rating by FBR Capital given on Monday, March 12. Jefferies maintained Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) rating on Monday, June 26. Jefferies has “Hold” rating and $200 target. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has “Neutral” rating given on Monday, February 12 by Cantor Fitzgerald. Chardan Capital Markets maintained the shares of ARWR in report on Thursday, November 10 with “Buy” rating. The firm has “Hold” rating given on Thursday, August 3 by Jefferies. FBR Capital maintained the shares of ARWR in report on Monday, February 12 with “Hold” rating. See Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) latest ratings:

09/05/2018 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Overweight Old Target: $5 Upgrade
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $4.0000 Maintain
27/03/2018 Broker: Jefferies Rating: Buy New Target: $10 Initiates Coverage On
12/03/2018 Broker: FBR Capital Rating: Hold Maintain
19/02/2018 Broker: Chardan Capital Markets Rating: Buy New Target: $7.0
12/02/2018 Broker: FBR Capital Rating: Hold New Target: $4.0 Maintain
12/02/2018 Broker: B. Riley & Co Old Rating: Neutral New Rating: Neutral Old Target: $3 New Target: $4 Maintain
12/02/2018 Broker: Cantor Fitzgerald Old Rating: Hold New Rating: Neutral Old Target: $2 New Target: $5 Maintain
05/01/2018 Broker: B. Riley & Co Rating: Neutral New Target: $3 Initiates Coverage On
04/01/2018 Broker: FBR Capital Rating: Hold New Target: $3.0

Director Jennifer Li of Philip Morris International Inc, obtained 40,000 of the Pinksheet-listed company shares valued at near $3.25 million US Dollars with an average of $81.3 stock price for a share . Presently, Jennifer Li owns 62,323 shares which are equivalent to about 0.00% of Philip Morris International Inc’s total market cap. Dated 15/05/2018 the transaction document is free at your disposal for review here.

Investors sentiment increased to 1.11 in 2017 Q4. Its up 0.14, from 0.97 in 2017Q3. It improved, as 74 investors sold Philip Morris International Inc. shares while 467 reduced holdings. 109 funds opened positions while 493 raised stakes. 1.09 billion shares or 0.42% less from 1.10 billion shares in 2017Q3 were reported. Hodges Management has 0.02% invested in Philip Morris International Inc. (NYSE:PM). Condor Mgmt holds 0.56% of its portfolio in Philip Morris International Inc. (NYSE:PM) for 25,895 shares. Bridges Investment Counsel reported 2.49% of its portfolio in Philip Morris International Inc. (NYSE:PM). Teachers Ins Annuity Association Of America owns 5,804 shares. Monarch Mngmt reported 13,745 shares. Tompkins accumulated 671 shares or 0.02% of the stock. Blb&B Ltd Co invested 0.23% of its portfolio in Philip Morris International Inc. (NYSE:PM). Swiss Bankshares owns 5.97M shares or 0.68% of their US portfolio. Bb&T Corp owns 262,642 shares. Cedar Hill Associates Lc accumulated 9,566 shares. Family Corporation reported 4,044 shares. Fil owns 675,965 shares. Walleye Trading Lc invested in 0.02% or 36,570 shares. Daiwa Sb Limited holds 86,970 shares. Pinnacle Assoc has invested 0.16% of its portfolio in Philip Morris International Inc. (NYSE:PM).

Analysts await Philip Morris International Inc. (NYSE:PM) to report earnings on July, 19. They expect $1.26 earnings per share, up 10.53% or $0.12 from last year’s $1.14 per share. PM’s profit will be $1.96B for 16.07 P/E if the $1.26 EPS becomes a reality. After $1.00 actual earnings per share reported by Philip Morris International Inc. for the previous quarter, Wall Street now forecasts 26.00% EPS growth.

Philip Morris International Inc., through its subsidiaries, makes and sells cigarettes, other tobacco products, and other nicotine-containing products. The company has market cap of $125.88 billion. The Company’s portfolio of brands comprises Marlboro, Merit, Parliament, Virginia S., L&M, Philip Morris, Bond Street, Chesterfield, Lark, Muratti, Next, and Red & White. It has a 20.87 P/E ratio. The firm also owns various cigarette brands, such as Dji Sam Soe, Sampoerna, and U Mild in Indonesia; Champion, Fortune, and Jackpot in the Philippines; Apollo-Soyuz and Optima in Russia; Morven Gold in Pakistan; Boston in Colombia; Belmont, Canadian Classics, and Number 7 in Canada; f6 in Germany; Delicados in Mexico; Assos in Greece; and Petra in the Czech Republic and Slovakia.

More notable recent Philip Morris International Inc. (NYSE:PM) news were published by: Finance.Yahoo.com which released: “A Look At The Fair Value Of Philip Morris International Inc (NYSE:PM)” on April 19, 2018, also Seekingalpha.com with their article: “Philip Morris adjusts full-year guidance” published on May 09, 2018, Seekingalpha.com published: “The Fall Of 2 Dividend Champions” on May 15, 2018. More interesting news about Philip Morris International Inc. (NYSE:PM) were released by: Seekingalpha.com and their article: “Philip Morris: No Dividend Cut Coming” published on April 23, 2018 as well as Fool.com‘s news article titled: “Why Philip Morris International Inc. Stock Lost 17.5% in April” with publication date: May 07, 2018.

Since February 21, 2018, it had 2 insider purchases, and 3 selling transactions for $13.98 million activity. Whitson Jerry also bought $248,282 worth of Philip Morris International Inc. (NYSE:PM) shares. 100,000 shares were sold by CAMILLERI LOUIS C, worth $8.21M on Wednesday, May 9. FIRESTONE MARC S sold $1.43 million worth of Philip Morris International Inc. (NYSE:PM) on Wednesday, February 21. $5.08 million worth of Philip Morris International Inc. (NYSE:PM) shares were sold by CALANTZOPOULOS ANDRE. Zielinski Miroslaw bought $489,360 worth of stock or 6,000 shares.

Among 21 analysts covering Philip Morris International (NYSE:PM), 16 have Buy rating, 1 Sell and 4 Hold. Therefore 76% are positive. Philip Morris International has $140.0 highest and $80 lowest target. $109.15’s average target is 34.79% above currents $80.98 stock price. Philip Morris International had 62 analyst reports since August 24, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Wednesday, January 4 by Bank of America. Vetr upgraded Philip Morris International Inc. (NYSE:PM) rating on Monday, August 24. Vetr has “Buy” rating and $92.62 target. Piper Jaffray maintained Philip Morris International Inc. (NYSE:PM) rating on Friday, October 13. Piper Jaffray has “Buy” rating and $135.0 target. JP Morgan upgraded Philip Morris International Inc. (NYSE:PM) on Friday, June 17 to “Overweight” rating. The stock has “Buy” rating by Cowen & Co on Friday, September 22. On Friday, October 20 the stock rating was maintained by Citigroup with “Neutral”. Jefferies maintained it with “Hold” rating and $120.0 target in Tuesday, September 26 report. The stock has “Buy” rating by Wells Fargo on Wednesday, November 15. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, August 31. Deutsche Bank initiated it with “Buy” rating and $12000 target in Tuesday, April 10 report.

The stock increased 1.31% or $1.05 during the last trading session, reaching $80.98. About 2.83M shares traded. Philip Morris International Inc. (NYSE:PM) has declined 13.93% since May 16, 2017 and is downtrending. It has underperformed by 25.48% the S&P500.

The stock decreased 1.03% or $0.1 during the last trading session, reaching $9.5. About 632,777 shares traded. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has risen 265.61% since May 16, 2017 and is uptrending. It has outperformed by 254.06% the S&P500.

Another recent and important Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news was published by Schaeffersresearch.com which published an article titled: “2 Upgraded Drug Stocks Squeezing Shorts” on May 09, 2018.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. The company has market cap of $832.07 million. The Company’s pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. It currently has negative earnings. The firm also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma.

Philip Morris International Inc. (NYSE:PM) Institutional Positions Chart

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: